Reparixin, an investigational allosteric inhibitor of CXCR1 and, to a lesser extent, of CXCR2 [5], reduced the metastatic spread of human BC cells and the CSC (both ALDH+ and CD24−/CD44+) content of human BC cell lines and xenografts in mice both as single agent and in combination with chemotherapy [4]. This evidence concerns the gene CD24 and breast cancer.